Marshall Wace LLP Makes New $8.27 Million Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Marshall Wace LLP purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 120,516 shares of the biopharmaceutical company's stock, valued at approximately $8,269,000.

A number of other hedge funds have also recently added to or reduced their stakes in GILD. Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company's stock valued at $8,404,161,000 after buying an additional 2,910,147 shares during the period. Capital World Investors lifted its holdings in Gilead Sciences by 1.4% in the first quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company's stock worth $6,189,435,000 after acquiring an additional 1,133,281 shares during the last quarter. Capital Research Global Investors boosted its stake in Gilead Sciences by 2.7% in the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company's stock valued at $4,486,296,000 after acquiring an additional 1,589,240 shares during the period. Wellington Management Group LLP grew its holdings in shares of Gilead Sciences by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company's stock valued at $1,509,227,000 after purchasing an additional 2,350,550 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Gilead Sciences by 2.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 10,412,413 shares of the biopharmaceutical company's stock worth $714,421,000 after purchasing an additional 268,208 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Trading Up 0.7 %

Shares of GILD opened at $83.61 on Monday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The company has a 50-day moving average of $78.05 and a 200 day moving average of $71.53. The firm has a market capitalization of $104.17 billion, a price-to-earnings ratio of 232.25, a PEG ratio of 2.91 and a beta of 0.18. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. On average, research analysts expect that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were given a $0.77 dividend. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.68%. Gilead Sciences's dividend payout ratio (DPR) is 855.56%.

Wall Street Analyst Weigh In

GILD has been the subject of several recent analyst reports. Evercore ISI raised Gilead Sciences to a "strong-buy" rating in a research note on Friday, August 9th. Truist Financial increased their price target on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a "hold" rating in a research note on Thursday, August 15th. Cantor Fitzgerald reiterated a "neutral" rating and set a $70.00 target price on shares of Gilead Sciences in a research report on Monday, September 16th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Finally, BMO Capital Markets raised their price objective on Gilead Sciences from $80.00 to $85.00 and gave the company an "outperform" rating in a research report on Friday, August 9th. Twelve analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $82.06.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.